# United States Drug Patent 8,080,530: Scope, Claims, Expiration, Orange Book Status, and Ivermectin Rosacea Patent Landscape

U.S. Patent No. 8,080,530 protects topical ivermectin emulsions formulated for rosacea treatment and, separately, the use of those emulsions in a rosacea treatment regimen. Its core limitation is not ivermectin alone. A potentially infringing product must generally combine ivermectin with specified concentration ranges, oil-phase components, emulsifiers, solvents or penetration agents, a carbomer-type gelling agent, water, and a 12-week chemical-stability requirement. The patent issued to Galderma S.A. and had a 20-year term measured from its earliest claimed priority date, with an expiration date of February 25, 2025, subject to any applicable patent-term adjustment or extension reflected in the official patent record.[1]

The patent is important to Soolantra, the FDA-approved ivermectin 1% cream for inflammatory lesions of rosacea. Its practical blocking value has declined because the patent term has ended or reached its scheduled expiration, while later Galderma patents and regulatory exclusivities may have created separate barriers to generic entry.

What does U.S. Patent 8,080,530 protect?

U.S. Patent 8,080,530 has two principal claim groups:

Claim group	Claims	Protected subject matter
Treatment-regimen claims	1-14	Topical application of an ivermectin emulsion to skin affected by rosacea
Composition claims	15-28	Stable topical ivermectin emulsions having specified ingredients and concentration ranges

The claims are formulation-specific. They do not broadly cover every topical ivermectin product, every use of ivermectin for rosacea, or ivermectin as an active ingredient by itself.

The patent’s commercial center is a topical oil-in-water emulsion containing approximately 1% ivermectin. The disclosed formula corresponds closely to the type of formulation used in Soolantra, although claim scope must be assessed against the exact marketed composition and any proposed generic formulation.

What is the central inventive concept?

The claimed technical combination is a chemically stable ivermectin emulsion suitable for topical administration. The composition uses:

An oily phase containing dimethicone, cyclomethicone, isopropyl palmitate, or isopropyl myristate;
Fatty alcohols, fatty acids, or self-emulsifiable wax;
Nonionic surfactant-emulsifiers;
Ivermectin at 0.1% to 5% by weight;
Solvents or penetration agents, including propylene glycol, oleyl alcohol, phenoxyethanol, or glyceryl triacetate;
A carbomer or acrylate C10-C30 alkyl acrylate crosspolymer;
Water; and
Chemical stability for at least 12 weeks.

The claims therefore combine active-ingredient identity, excipient identity, quantitative ranges, dosage form, therapeutic use, and stability.

How do claims 1 through 4 define rosacea treatment?

Claims 1 through 4 are method-of-treatment claims. Each requires:

An individual in need of rosacea treatment;
Topical application to the affected skin area;
A topical pharmaceutical composition containing an effective amount of ivermectin;
An emulsion dosage form;
Specified excipients and concentration ranges; and
Chemical stability for 12 weeks.

Claim 1 is the broadest of the principal treatment claims because it allows multiple alternatives within the oily phase, fatty substances, emulsifiers, solvents, and carbomer components.

Claim 2 narrows the oily phase and gelling-agent language, including an acrylate C10-C30 alkyl acrylate crosspolymer. Claim 3 narrows the composition further to a combination centered on dimethicone, isopropyl palmitate, cetyl alcohol, stearyl alcohol, sorbitan monostearate, Ceteareth-20, and selected solvents. Claim 4 recites a particularly specific combination of those ingredients.

A product may fall outside a narrower dependent claim while still falling within a broader independent claim. This makes claims 1 and 15 the principal claims for preliminary infringement screening.

What do claims 15 through 18 protect?

Claims 15 through 18 are composition claims and do not require that the product actually be used to treat rosacea.

Claim	Main scope
15	Broad stable ivermectin emulsion using the broader alternative ingredient lists
16	Narrower stable emulsion using the specified acrylate crosspolymer
17	Emulsion containing dimethicone, isopropyl palmitate, cetyl alcohol, stearyl alcohol, sorbitan monostearate, Ceteareth-20, and selected solvents
18	More specific composition corresponding to the claim 4 formulation

The composition claims create a potentially significant enforcement route because a finished product, imported product, or manufacturing batch could infringe without evidence of the manufacturer’s intended rosacea indication. Claims 15 through 18 also have relevance to formulation suppliers, contract manufacturers, and importers.

What formulation is recited in claims 9 and 23?

Claims 9 and 23 recite substantially the same detailed formulation. The principal ingredients and concentrations are:

Ingredient	Approximate amount, % w/w
Ivermectin	1.00
Glycerol	4.00
Acrylate C10-C30 alkyl acrylate crosspolymer	0.15
Methyl parahydroxybenzoate	0.20
Disodium EDTA	0.05
Citric acid monohydrate	0.05
Isopropyl myristate	4.00
Cetyl alcohol	3.00
Stearyl alcohol	2.00
Self-emulsifiable wax	0.80
Palmitostearic acid	0.50
Steareth-20	2.00
Sorbitan palmitate	1.00
Dimethicone 20	0.50
Propyl parahydroxybenzoate	0.10
Propylene glycol	4.00
Glyceryl triacetate	1.00
Phenoxyethanol	0.50
Water	Quantity sufficient to 100%

These claims are narrow but commercially important. A generic formulation that copies the qualitative and quantitative structure could face direct literal-infringement risk if the patent remained enforceable and the formula satisfied the stability limitation.

When did U.S. Patent 8,080,530 expire?

The patent’s earliest priority date is February 25, 2004. The ordinary 20-year term therefore runs to February 25, 2025, subject to any patent-term adjustment or other statutory modification recorded by the USPTO.[1]

Event	Date
Earliest claimed priority	February 25, 2004
U.S. patent application filing	February 25, 2005
Patent grant	December 20, 2011
Scheduled 20-year expiration	February 25, 2025
Patent-term extension under Hatch-Waxman	No extension is identified here

The expiration of this patent does not automatically eliminate all Soolantra exclusivity. Later formulation, use, manufacturing, or regulatory protections must be reviewed separately.

What is the FDA and Orange Book status of the patent?

Soolantra, containing ivermectin 1% cream, was approved by the FDA on December 23, 2014, under NDA 206255 for the treatment of inflammatory lesions of rosacea in adults.[2]

The Orange Book identifies patent and exclusivity information submitted by the NDA holder. Orange Book listing is product-specific and does not itself determine the ultimate scope or validity of a patent. For an ANDA applicant, listed patents can trigger a Paragraph IV certification and patent litigation under the Hatch-Waxman framework.[3]

The relevant regulatory points are:

Regulatory issue	Assessment
Reference drug	Soolantra ivermectin 1% cream
NDA holder	Galderma Laboratories, L.P. and related Galderma entities
FDA approval	December 23, 2014
Regulatory pathway for generics	ANDA
Biosimilar pathway	Not applicable
Patent challenge mechanism	Paragraph IV certification
Exclusivity type	Small-molecule drug exclusivity, not biologic exclusivity

A generic applicant could certify that the patent had expired, would expire before launch, was not infringed, or was invalid. A Paragraph IV notice could result in a 30-month stay if the NDA holder filed a timely infringement action.[3]

Which products compete with Soolantra?

The competitive field includes branded ivermectin cream, generic ivermectin cream, and non-ivermectin rosacea therapies.

Product or category	Active ingredient	Dosage form	Patent-risk profile
Soolantra	Ivermectin 1%	Topical cream	Original reference product; later patent layers may apply
Generic ivermectin cream	Ivermectin 1%	Topical cream	ANDA and Paragraph IV exposure
Rozex and generic metronidazole	Metronidazole	Gel, cream, lotion	Different active ingredient and formulation estate
Finacea and generic azelaic acid	Azelaic acid	Foam or gel	Separate formulation and method claims
Oracea and generic doxycycline	Doxycycline	Oral capsule	Systemic therapy; different regulatory and patent issues
Brimonidine topical products	Brimonidine	Gel	Vasoconstrictor-based rosacea treatment

Ivermectin cream competes primarily on inflammatory-lesion efficacy, once-daily topical use, and a formulation designed for chronic facial application. A generic can avoid the ’530 patent only if its composition and use do not meet the relevant claim limitations or if the patent is no longer enforceable.

How strong is the patent estate for ivermectin rosacea products?

The ’530 patent is strongest against formulations that reproduce the claimed excipient architecture. Its strength is lower against:

Ivermectin products using a non-emulsion vehicle;
Products outside the stated ingredient classes or concentration ranges;
Products using a different gelling system;
Products that do not satisfy the chemical-stability limitation;
Non-rosacea uses, unless another claim or patent applies;
Products supported by a non-infringement position based on claim construction.

Its claim breadth is constrained by several cumulative limitations. The composition must contain the required ingredients within the claimed ranges, and an accused product must meet each limitation of at least one asserted claim.

The 12-week chemical-stability requirement is particularly important. It is not merely a manufacturing preference. If treated as a claim limitation, the patent owner would need to establish that the accused emulsion satisfies the stability requirement under the claim’s construction and evidentiary standard.

What are the main validity pressure points?

Potential validity issues include:

Earlier topical ivermectin or emulsion disclosures;
Obviousness based on combining known ivermectin with conventional dermatological excipients;
Written-description support for the breadth of the Markush groups;
Enablement across the full ingredient and concentration ranges;
Definiteness of the stability limitation;
Whether the claimed formulation delivers an unexpected technical effect; and
Whether the method claims add a patentable distinction beyond the composition itself.

The patent’s strongest validity defense would likely rely on formulation stability, compatibility, and the selection of excipient combinations rather than on ivermectin’s identity alone.

What generic entry risks exist?

A generic manufacturer faces four principal risks:

Direct infringement of composition claims 15 through 18;
Induced or contributory infringement allegations involving rosacea labeling;
Litigation triggered by a Paragraph IV certification;
Separate exposure under later Galderma patents covering the product, formulation, method of use, or manufacturing process.

A “skin cream” formulation that contains ivermectin at 1% is not automatically outside the patent. Ingredient selection must be mapped against every limitation. Conversely, the presence of ivermectin and an emulsion alone does not establish infringement.

A generic launch after February 25, 2025 reduces exposure to the ’530 patent but does not resolve later patents or regulatory requirements. The commercial launch date must therefore be modeled against the entire Orange Book listing and any non-Orange Book patent assertions.

Are biosimilar risks relevant?

No. Ivermectin is a small-molecule drug, and Soolantra is not a biologic. The applicable competitive pathway is an ANDA for a generic drug, not a biosimilar application under the Biologics Price Competition and Innovation Act.

The relevant barriers are formulation equivalence, inactive-ingredient safety, topical bioequivalence or comparative clinical requirements, manufacturing controls, labeling, and patent certifications.

What licensing and settlement issues affect the landscape?

The principal commercial rights are associated with Galderma and its Soolantra product. No material public license or settlement specific to U.S. Patent 8,080,530 is established by the claim text supplied. Any definitive assessment of generic launch timing requires review of FDA Orange Book updates, district-court dockets, ANDA litigation complaints, settlement agreements, and later Galderma patent families.

Settlements can create licensed-entry dates that differ from patent expiration. They can also contain restrictions involving authorized generic supply, product launch conditions, or patent challenges. A patent expiration date alone does not disclose those commercial terms.

What geographic coverage does the patent provide?

U.S. Patent 8,080,530 provides rights in the United States. Corresponding foreign applications may have produced separate patents with different claims, expiration dates, prosecution histories, and enforceability.

The patent’s U.S. claims can affect:

Manufacture in the United States;
Importation of infringing ivermectin emulsions;
Commercial sale;
Offers for sale;
Use of the claimed treatment regimen; and
Contract manufacturing for a U.S. market.

Foreign launch analysis requires a separate country-by-country family review. U.S. expiration does not terminate counterpart rights in Europe, Canada, Japan, Australia, or other jurisdictions.

Key Takeaways

U.S. Patent 8,080,530 covers specified ivermectin emulsions and their use for rosacea.
Claims 1-14 are treatment-regimen claims; claims 15-28 are composition claims.
The principal limitations are ivermectin concentration, emulsion structure, excipient classes, gelling agent, water, and 12-week chemical stability.
Claims 9 and 23 recite a detailed 1% ivermectin formulation closely aligned with the commercial formulation architecture.
The scheduled U.S. patent expiration date is February 25, 2025.
Soolantra was FDA-approved on December 23, 2014, under NDA 206255.
Generic ivermectin cream applicants use the ANDA pathway and may submit Paragraph IV certifications.
Biosimilar analysis is not relevant because ivermectin is a small molecule.
Expiration of the ’530 patent does not eliminate risk from later Galderma patents, regulatory exclusivity, litigation settlements, or non-Orange Book rights.
The most important diligence task is a complete product-to-claim chart against the full Soolantra patent estate.

FAQs

Can a 1% ivermectin cream infringe U.S. Patent 8,080,530?

Yes, but ivermectin concentration alone is insufficient. Infringement depends on whether the product also meets the required emulsion, excipient, concentration, gelling-agent, water, and stability limitations of an asserted claim.

Does the patent cover oral ivermectin?

No. The asserted claims are directed to topical emulsions and topical treatment of rosacea. Oral ivermectin is outside these claims unless another patent applies.

Does the patent cover ivermectin lotion or gel products?

Not automatically. A lotion or gel may avoid the claims if it is not the claimed emulsion or does not contain the required ingredient classes and concentration ranges.

Is chemical stability a required infringement element?

Yes, where the asserted claim includes the 12-week stability limitation. The parties would likely dispute the meaning, testing method, and evidentiary proof of that limitation.

Can a generic launch immediately after February 25, 2025?

Not necessarily. The ’530 patent’s scheduled expiration may remove one barrier, but later patents, regulatory requirements, litigation settlements, and other enforceable rights can delay or restrict launch.

References

United States Patent and Trademark Office. (2011). U.S. Patent No. 8,080,530, pharmaceutical compositions comprising ivermectin.
U.S. Food and Drug Administration. (2014). Soolantra (ivermectin) cream, 1%: Prescribing information. Galderma Laboratories, L.P.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	03 05048	Apr 24, 2003

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1620113	⤷ Start Trial	C300756	Netherlands	⤷ Start Trial
European Patent Office	1620113	⤷ Start Trial	CA 2015 00045	Denmark	⤷ Start Trial
European Patent Office	1620113	⤷ Start Trial	PA2015033	Lithuania	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,080,530

Summary for Patent: 8,080,530